

| ARH site 2015 and 2016 ANTIBIOGRAM ICU and HAU (% Susceptible ^a) | | GRAM POSITIVE | | | GRAM NEGATIVE | | | |
|--|--|---|--|--|--|-------------------------|---|--|
| | | <i>Staphylococcus aureus</i> (MSSA + MRSA) | <i>MRSA</i> (Methicillin Resistant <i>Staph. aureus</i>) | <i>MSSA</i> (Methicillin Susceptible <i>Staph. aureus</i>) | <i>Enterobacter cloacae</i> ^{b,g} | <i>Escherichia coli</i> | <i>Klebsiella pneumoniae</i> ^g | <i>Pseudomonas aeruginosa</i> ^g |
| Number of Isolates | | 91 | 35 | 56 | 14 | 47 | 26 | 28 |
| Penicillins | Cloxacillin | 62 | R | 100 | R | R | R | R |
| | Penicillin (IV) | N | R | N | R | R | R | R |
| | Penicillin (Oral) | | | | | | | |
| | Ampicillin/Amoxicillin | N | R | N | R | 36 | R | R |
| | Amoxicillin-Clavulanate | | R | | R | 79 | 85 | R |
| | Piperacillin-Tazobactam | | R | | N | 92 | 85 | 75 |
| Cephalosporins | Cephalexin - 1st gen | 62 | R | 100 | R | 47 ^e | 81 ^e | R |
| | Cefazolin ^c - 1st gen | 62 | R | 100 | R | 68 | 81 | R |
| | Cefuroxime - 2nd gen | | | | R | | | R |
| | Cefixime - 3rd gen | | R | | N | 79 | 81 | R |
| | Cefotaxime / Ceftriaxone - 3rd gen | | R | | N | 83 | 81 | R |
| | Ceftazidime - 3rd gen | | R | | N | | | 75 |
| Carbapenems | Ertapenem - restricted | | R | | 93 | 99 | 92 | R |
| | Imipenem - restricted | | R | | | | | 64 |
| | Meropenem - restricted | | R | | 99 | 99 | 92 | 64 |
| AMGs | Gentamicin | N | N | N | 100 | 83 | 92 | 86 |
| | Tobramycin | N | N | N | 100 | 77 | 92 | 96 |
| | Amikacin | N | N | N | 100 | 98 | 96 | 96 |
| FQs | Ciprofloxacin | N | N | N | 93 | 60 | 92 | 86 |
| | Levofloxacin | | | | | | | |
| | Moxifloxacin | N | N | N | N | N | N | N |
| Miscellaneous | Erythromycin ^f | 54 | 6 | 84 | R | R | R | R |
| | Clindamycin | 62 | 23 | 86 | R | R | R | R |
| | Doxycycline | 100 | 100 | 100 | | | | R |
| | Linezolid - restricted | 100 | 100 | | R | R | R | R |
| | Metronidazole | R | R | R | R | R | R | R |
| | Nitrofurantoin-simple cystitis only ^e | 98 | 97 | 98 | 21 | 87 | 31 | R |
| | TMP-SMX or Cotrimoxazole | 98 | 97 | 98 | 93 | 77 | 89 | R |
| | Vancomycin | 100 ^d | 100 ^d | 100 ^d | R | R | R | R |

This susceptibility chart is provided as a guide to empiric therapy until culture and susceptibility results are available.

KEY

- R = Intrinsically resistant
- = Susceptibility not tested
- N = Not recommended
- ☺ = Synergy with ampicillins or vancomycin

NOTES:

- a. This antibiogram includes only the first isolate of a specific organism from any patient.
- b. *Enterobacter* carries inducible cephalosporinases (AmpC) that cause *in-vivo* resistance to 3rd generation cephalosporins.
- c. Interpretation based on dose of cefazolin 2g IV q8h.
- d. Some *S. aureus* isolates with an MIC of 2 will be interpreted as susceptible but may result in clinical failure.
- e. For urinary tract isolates only.
- f. Susceptibility to erythromycin for these organisms is the same as for azithromycin/ clarithromycin.
- g. Calculated from fewer than the standard recommendation of a minimum of 30 isolates.

Developed by:
Dr. Neil Mina, FH Medical Microbiologist and
Bryna Yao, FH Regional LIS Coordinator